Outcome Measures
The primary outcome for this analysis was the change in impairment measured by the FMA-UE score after completion of the 6-weeks in-clinic therapy. Secondary endpoints were change in FMA-UE score and Wolf Motor Function Test (WMFT) at day-90 after completion of in-clinic therapy, and clinically important response rate, defined as a greater than or equal to 6-point change in FMA-UE score at 90 days after in-clinic therapy